These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 710487)

  • 1. Circadian dependence of host and tumor responses to cyclophosphamide in mice.
    Cardoso SS; Avery T; Venditti JM; Goldin A
    Eur J Cancer (1965); 1978 Sep; 14(9):949-54. PubMed ID: 710487
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract]   [Full Text] [Related]  

  • 3. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
    Scheving LE; Burns ER; Pauly JE; Halberg F
    Cancer Res; 1980 May; 40(5):1511-5. PubMed ID: 7370988
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronochemotherapy: L 1210 leukemia and beyond.
    Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA
    Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
    Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 7. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of microsomal enzyme modifiers on toxicity and therapeutic activity of cyclophosphamide in mice.
    Hart LG; Adamson RH
    Arch Int Pharmacodyn Ther; 1969 Aug; 180(2):391-401. PubMed ID: 5348409
    [No Abstract]   [Full Text] [Related]  

  • 9. Schedule-dependent cytotoxicity of 5-fluorouracil and cyclophosphamide in experimental cancer chemotherapy.
    Mulder JH; Smink T; Ossewaarde T; van Putten LM
    Eur J Cancer (1965); 1980 May; 16(5):699-705. PubMed ID: 6930341
    [No Abstract]   [Full Text] [Related]  

  • 10. Adriamycin/cyclophosphamide combination chemotherapy: the importance of drug scheduling.
    Mulder JH; van Putten LM
    Eur J Cancer (1965); 1979 Dec; 15(12):1503-9. PubMed ID: 294960
    [No Abstract]   [Full Text] [Related]  

  • 11. A dose-response study of resistance of leukemia L1210 to cyclophosphamide.
    DeWys WD
    J Natl Cancer Inst; 1973 Mar; 50(3):783-9. PubMed ID: 4708156
    [No Abstract]   [Full Text] [Related]  

  • 12. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
    Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
    Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
    Stoychkov JN; Milushev AS; Todorov DK
    Neoplasma; 1980; 27(1):33-6. PubMed ID: 6892839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic performance of carminomycin-cyclophosphamide against L1210 leukemia.
    Avery TL; Cruze PG
    Cancer Res; 1978 Sep; 38(9):2892-5. PubMed ID: 679196
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
    Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
    Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium iodide--doses it potentiate the activity of cyclophosphamide?
    Hart MM; Adamson RH
    Lancet; 1971 Jun; 1(7711):1243. PubMed ID: 4103105
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronomodulatory effect of cyclosporine upon survival of DBA mice with L1210 leukemia.
    Sánchez de la Peña S; Halberg E; Halberg F; Sánchez E; Cornélissen G
    Chronobiologia; 1986; 13(2):129-35. PubMed ID: 3731947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice.
    Hacker MP; Ershler WB; Newman RA; Gamelli RL
    Cancer Res; 1982 Nov; 42(11):4490-4. PubMed ID: 6290038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.